Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003622priorityCriticalpatent/ECSP003622A/en
Publication of ECSP003622ApublicationCriticalpatent/ECSP003622A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
El invento se refiere a una nueva combinación de sustancias activas para el tratamiento mas eficaz del sindrome de piernas inquietas (RLS), que consta de un agente agonista a2 y de otro neuro-psicofármaco que reduce los síntomas del RLS como una monoterapia.The invention relates to a new combination of active substances for the most effective treatment of restless legs syndrome (RLS), consisting of an a2 agonist agent and another neuro-psychoactive drug that reduces the symptoms of RLS as a monotherapy.
ECSP0036222000-08-142000-08-14
DRUG LEG SYNDROME MEDICINAL TREATMENT
ECSP003622A
(en)
Oral dosage form comprising at least one nicotine active agent, at least one bioadhesive material capable of forming a hydrogen bond with the nicotine active agent, and at least one rapidly releasing sensory impact agent; and its use to provide rapid relief from nicotine cravings (div. sol. 1825-04).
Lozenge composition comprising: a) a standard granule with at least: an alkaline buffering agent, a dissolution modifier and a filler, b) a defined extragranular nicotine active ingredient and at least one alkaline buffering agent; preparation procedure; Useful to eliminate or reduce tobacco use.
Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a tonicity regulating glycol based agent, use of the composition for the manufacture of a medicament for the treatment of ophthalmic disorders